)
)
Company research26 Mar 2024
Companies That Had Their IPO in 1989: The Calm Between the Storms
A look at the IPO landscape and market sentiment in 1989 as the markets enjoyed a period of relative calm between tumultuous times.
Sanofi
Sanofi (SAN) investor relations material
Sanofi Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary30 Oct, 2026
Executive summary
Q3 net sales were €14.444bn, up 14.3% at CER; business EPS rose 19.6% at CER to €3.55.
Growth was led by Dupixent and pharma launches; vaccines declined amid seasonal delivery phasing and lower Beyfortus sales.
FY2026 sales and business EPS guidance was upgraded; priorities include profitable growth, R&D productivity and sustaining growth through Dupixent’s loss of exclusivity.
Financial highlights
Q3 net sales were €14.444bn, up 14.3% at CER and 16.2% at actual rates; YTD sales were €36.550bn, up 15.2% at CER.
Business operating income was €5.430bn, up 19.7% at CER; business net income was €4.255bn, up 17.6% at CER.
IFRS net income attributable to equity holders was €3.021bn in Q3 and €4.979bn YTD; YTD business net income was €9.020bn.
Pharma launches generated €2.176bn in Q3, up 19.2% at CER and representing 15% of sales.
Outlook and guidance
FY2026 sales growth guidance was upgraded to low teens at CER; business EPS growth guidance was upgraded to mid-teens at CER.
FY2026 vaccine sales are expected to decline by a low-single-digit percentage; effective tax rate ambition is ~21%.
At October 2026 average exchange rates, expected currency impacts are -1% on sales and -1% on business EPS.
The 2027 early view is demand-led growth, slightly negative pricing and ~€1.3bn of sales impact from Cheplapharm and Medley divestments, subject to closing.
2030 sales ambitions are ~€25bn for Dupixent, ~€10bn for launches and ~€9bn for vaccines, at CER.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Sanofi
- Portfolio review and external innovation target durable pipeline output and selective growth.SAN
Bank of America Global Healthcare Conference - Four long-acting antibodies extend the alliance with 50/50 development and profit sharing.SANCollaboration
- Strategic focus on specialty care, pipeline rigor, and flexible deal-making drive future growth.SANMorgan Stanley 24th Annual Global Healthcare Conference
- Q2 2026 saw double-digit sales and EPS growth, upgraded guidance, and major pipeline progress.SANQ2 2026
- Pipeline progress, margin expansion, and strategic investments drive future growth.SANMorgan Stanley 23rd Annual Global Healthcare Conference
- 2025 delivered double-digit sales and EPS growth, led by innovation and strong capital returns.SANQ4 2025
- Tolebrutinib delayed disability progression in MS by up to 31% with manageable liver risk.SANStatus Update
- Q3 sales up 16% CER to €13.4B, with upgraded EPS guidance and strong pipeline momentum.SANQ3 2024
- Double-digit growth, strong pipeline, and €5bn buyback set up robust 2025 outlook.SANQ4 2024
Next Sanofi earnings date
Jefferies Global Healthcare Conference17 Nov, 2026
Sanofi
Next Sanofi earnings date
Jefferies Global Healthcare Conference17 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Sanofi is an integrated global biopharmaceutical company, focused on patient needs and engaged in the research, development, manufacturing, marketing and distribution of innovative therapies that improve lives. Sanofi has core strengths in diabetes solutions, human vaccines and innovative drugs for rare diseases.Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. The company's sales channels include pharmaceutical products sold directly to retail pharmacies and wholesale distributors, as well as through hospitals, clinics, mail order and specialty pharmacies.